Granzyme B

Granzyme B

Granzyme B is a serine protease enzyme that plays a crucial role in the immune system, particularly in the process of inducing apoptosis in target cells. It is one of the key components of the cytotoxic granules found in cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. These immune cells utilize granzyme B to eliminate virus-infected cells and tumor cells, thereby contributing to the body's defense mechanisms.

Structure and Function

Granzyme B is a member of the granzyme family of serine proteases, which are characterized by their ability to cleave peptide bonds in proteins. The enzyme is synthesized as an inactive zymogen and is activated upon entry into the target cell. Granzyme B is stored in the cytotoxic granules of CTLs and NK cells, along with other proteins such as perforin.

Upon recognition of a target cell, CTLs and NK cells release their granules into the immunological synapse formed between the immune cell and the target cell. Perforin facilitates the entry of granzyme B into the target cell by forming pores in the target cell membrane. Once inside, granzyme B cleaves specific substrates, leading to the activation of caspases and the induction of apoptosis.

Mechanism of Action

Granzyme B initiates apoptosis by cleaving and activating caspases, which are a family of cysteine proteases that play essential roles in programmed cell death. Granzyme B preferentially cleaves after aspartic acid residues, similar to caspases, and can directly activate caspase-3, one of the key executioner caspases in the apoptotic pathway.

In addition to activating caspases, granzyme B can cleave other substrates, such as the pro-apoptotic Bcl-2 family member Bid, which leads to mitochondrial outer membrane permeabilization and the release of cytochrome c, further amplifying the apoptotic signal.

Clinical Significance

Granzyme B is a critical component of the immune response against viral infections and cancer. Its ability to induce apoptosis in target cells makes it a potential therapeutic target for enhancing immune responses in cancer immunotherapy. However, dysregulation of granzyme B activity can contribute to autoimmune diseases and tissue damage, highlighting the need for precise regulation of its activity.

Research and Applications

Research on granzyme B has focused on understanding its role in immune surveillance and its potential as a therapeutic target. Studies have explored the use of granzyme B inhibitors to modulate immune responses in autoimmune diseases and to protect tissues from immune-mediated damage.

In cancer therapy, strategies to enhance granzyme B activity or delivery to tumor cells are being investigated to improve the efficacy of immunotherapies. Additionally, granzyme B is used as a biomarker for the activity of CTLs and NK cells in various diseases.

Also see

• Perforin
• Caspase
• Apoptosis
• Cytotoxic T lymphocyte
• Natural killer cell